Related Experiment Video
Updated: Jan 9, 2026
Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
Published on: February 2, 2024
Reduced FEV3/FVC as an Early Indicator of COPD in Individuals with Normal Spirometry: A Prospective Analysis from the
Yuemao Li1, Jingwen Li1, Suyin Huang1,2
1State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Purpose:
This study aimed to evaluate the association between the forced expiratory volume in 3 s (FEV3) to forced vital capacity (FVC) and computed tomography (CT)-defined abnormalities, and to assess its potential value in predicting incident chronic obstructive pulmonary disease (COPD) over a 3-year period.
Participants And Methods:
This 3-year community-based cohort study enrolled participants with normal lung function (post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted). Baseline assessments included questionnaires, spirometry, CT scans, and impulse oscillometry. Participants were stratified by post-bronchodilator FEV3/FVC tertiles. Outcomes included acute respiratory events, annual lung function decline, and COPD incidence. Data were analyzed using mixed-effects models, log-binomial regression, and zero-inflated negative binomial models.
Results:
Of the 981 participants with normal baseline lung function stratified by post-bronchodilator FEV3/FVC tertiles (high: ≥95.5%, medium: 91.9-95.4%, low: ≤91.8%), 807 completed the 3-year follow-up. Compared to the high-FEV3/FVC group, participants in the low-FEV3/FVC group tended to be older (60.5 vs 55.7 years) and included more males (80.4% vs 38.8%) and smokers. The low-FEV3/FVC group also demonstrated a lower baseline post-bronchodilator FEV1/FVC (74.0% vs 85.1%) and higher prevalence of emphysema (53.5% vs 18.3%). Longitudinal analysis revealed a greater annual post-bronchodilator FEV1 decline in the low-FEV3/FVC group (adjusted mean difference: 10 mL, 95% confidence interval [CI]: 0 to 21mL; p = 0.043) and an increased risk of developing COPD (19.4% versus 1.9%; adjusted relative risk: 4.96, 95% CI: 1.96-12.51; p = 0.001) than the high-FEV3/FVC group, with no difference in acute respiratory events.
Conclusion:
A reduced FEV3/FVC ratio was associated with an increased risk of accelerated lung function decline and progression to COPD in individuals with normal spirometry. As a readily accessible measure derived from routine spirometry, FEV3/FVC may have a role in early COPD detection.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...